" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Products>This Product
  Products


MaxDiscovery™ Alkaline Phosphatase (AP) Enzymatic Assay Kit

Product Description
The MaxDiscovery™ Alkaline Phosphatase (AP) Enzymatic Assay Kit is a plate-based, colorimetric-endpoint assay for the determination of the alkaline phosphatase enzyme in serum. Alkaline phosphatase (AP) is a ubiquitously-expressed intracellular enzyme which catalyzes the hydrolysis of organic phosphoesters. AP is a clinically important protein marker in serum because its level changes in response to a number of health-related states. For example, changes in AP serum levels are often caused by liver and liver and bone diseases. Also, the presence of elevated levels of the enzyme in serum after administration of drugs and experimental therapeutic agents is associated with organ toxicity. Therefore, monitoring serum levels of AP enzyme has become a routine method to monitor drug toxicity. MaxDiscovery™ Alkaline Phosphatase Enzymatic Assay Kit uses an enzymatic assay to determine the amount of alkaline phosphatase in rodent serum and other liquid samples. The kit enables biomedical researchers to determine alkaline phosphatase levels in liquid samples such as serum. The MaxDiscovery™ Alkaline Phosphatase Enzymatic Assay Kit contains sufficient materials to test 42 samples in duplicate. The assay utilizes a simple colorimetric (visible) enzymatic assay to specifically detect AP in fluids. The MaxDiscovery™ Alkaline Phosphatase Enzymatic Assay Kit provides accurate, proven results even in complex liquid mixtures. The kit is designed to be used with a microplate reader. The kit contains a thymolphthalein standard to construct a linear calibration curve and verify assay performance.
Product MaxDiscovery™ Alkaline Phosphatase (AP) Enzymatic Assay Kit
Company BIOO Scientific - Product Directory
Price Request a quote
More Information View company product page
Catalog Number 3460-03
Quantity 1 x 96 wells
Company Logo

BIOO Scientific - Product Directory
3913 Todd Lane Suite 312 Austin, TX 78744, USA

Tel: +1 512-707-8993
Fax: +1 512-707-8122
Email: info@biooscientific.com



Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Scroll Up
Scroll Down

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!